Moreover, the 36-month beta value for BEAM is 1.90. Analysts have varying opinions on the stock, with 7 analysts rating it as a “buy,” 5 as “overweight,” 8 as “hold,” and 0 as “sell.”
The public float for BEAM is 72.00M and currently, short sellers hold a 17.10% of that float. On November 15, 2024, BEAM’s average trading volume was 908.44K shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
BEAM) stock’s latest price update
The stock price of Beam Therapeutics Inc (NASDAQ: BEAM) has plunged by -4.33 when compared to previous closing price of 27.50, but the company has seen a 0.80% gain in its stock price over the last five trading sessions. globenewswire.com reported 2024-11-12 that CAMBRIDGE, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) — Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that John Evans, chief executive officer of Beam, plans to participate in a fireside chat during the 2024 Jefferies London Healthcare Conference on Tuesday, November 19, 2024, at 10:00 a.m. GMT in London.
BEAM’s Market Performance
Beam Therapeutics Inc (BEAM) has seen a 0.80% rise in stock performance for the week, with a -1.42% decline in the past month and a 7.70% surge in the past quarter. The volatility ratio for the week is 9.73%, and the volatility levels for the past 30 days are at 6.94% for BEAM. The simple moving average for the last 20 days is 8.04% for BEAM stock, with a simple moving average of -1.92% for the last 200 days.
Analysts’ Opinion of BEAM
Many brokerage firms have already submitted their reports for BEAM stocks, with Leerink Partners repeating the rating for BEAM by listing it as a “Outperform.” The predicted price for BEAM in the upcoming period, according to Leerink Partners is $39 based on the research report published on November 06, 2024 of the current year 2024.
H.C. Wainwright gave a rating of “Buy” to BEAM, setting the target price at $80 in the report published on July 23rd of the current year.
BEAM Trading at 7.45% from the 50-Day Moving Average
After a stumble in the market that brought BEAM to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -46.85% of loss for the given period.
Volatility was left at 6.94%, however, over the last 30 days, the volatility rate increased by 9.73%, as shares surge +8.05% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +8.81% upper at present.
During the last 5 trading sessions, BEAM rose by +0.80%, which changed the moving average for the period of 200-days by +7.83% in comparison to the 20-day moving average, which settled at $24.35. In addition, Beam Therapeutics Inc saw -3.34% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at BEAM starting from Ciaramella Giuseppe, who sale 51,110 shares at the price of $26.36 back on Nov 06 ’24. After this action, Ciaramella Giuseppe now owns 109,150 shares of Beam Therapeutics Inc, valued at $1,347,050 using the latest closing price.
Ciaramella Giuseppe, the President of Beam Therapeutics Inc, sale 51,110 shares at $26.27 during a trade that took place back on Oct 14 ’24, which means that Ciaramella Giuseppe is holding 160,260 shares at $1,342,752 based on the most recent closing price.
Stock Fundamentals for BEAM
Current profitability levels for the company are sitting at:
- -0.52 for the present operating margin
- 0.94 for the gross margin
The net margin for Beam Therapeutics Inc stands at -0.41. The total capital return value is set at -0.18. Equity return is now at value -18.29, with -11.67 for asset returns.
Based on Beam Therapeutics Inc (BEAM), the company’s capital structure generated 0.17 points at debt to capital in total, while cash flow to debt ratio is standing at -0.84. The debt to equity ratio resting at 0.2. The interest coverage ratio of the stock is -4.76.
Currently, EBITDA for the company is -156.47 million with net debt to EBITDA at 0.45. When we switch over and look at the enterprise to sales, we see a ratio of 6.04. The liquidity ratio also appears to be rather interesting for investors as it stands at 5.69.
Conclusion
To wrap up, the performance of Beam Therapeutics Inc (BEAM) has been mixed in recent times. The stock has received a mixed of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
